Shadow Lake Group Inc. Announcing New Managing Director
TORONTO--(BUSINESS WIRE)--Mar 5, 2019--We are extremely excited to announce that Dr. Rochelle Seide has joined Shadow Lake Group as a Managing Director.
Dr. Seide has spent more than 30 years as a life sciences lawyer and business executive specializing in intellectual property matters. She has significant business development, portfolio management, licensing, and litigation experience including a deal sheet of more than $4.5 billion in transaction value. Rochelle’s background and expertise will be extremely helpful to Shadow Lake Group’s client base.
About Shadow Lake Group
Shadow Lake Group is a global boutique advisory firm that provides strategic advice and assistance with mergers & acquisitions, licensing and strategic consulting to life science companies worldwide. We are a team of healthcare, scientific and business specialists who are innovative, creative and driven to provide the best solutions to meet the demands of our clients. Our team possesses the caliber and quality of relationships found in some of the largest advisory firms along with the personalized service you expect from a boutique firm. Our breadth of knowledge and experience allows us to provide services and strategic advice at every step of the business process. www.shadowlakegroup.com
About Rochelle Seide
Dr. Seide has over 30 years of experience as a life sciences lawyer and business executive specializing in intellectual property, business development, transactions, portfolio management, licensing, and litigation.
From June 2014 through June 2018, Dr. Seide served as Vice President, Legal and Intellectual Property at HLS Therapeutics Inc., a Canadian pharmaceutical start-up which went public in March 2018. While at HLS, she provided legal counsel on a wide variety of matters for the company. Previously, Dr. Seide served as Vice President, Intellectual Property at Biovail Corporation, where she was resident at Biovail Laboratories International SRL (Barbados), the company’s chief operating subsidiary. In that capacity, she oversaw the management, exploitation, and leverage of Biovail’s significant IP portfolio; represented the company in all transactions relating to IP and asset acquisitions and licensing; and oversaw and managed the company’s IP related litigations in the US and Canada (including settlement negotiations). She left the company following its merger with Valeant.
Prior to Biovail, Dr. Seide spent nearly 25 years in private legal practice, primarily representing clients in the life sciences, including serving as a Partner in Baker Botts, LLP, where she was co-head of the Biotechnology practice; a Partner in Arent Fox, LLP, and Senior Counsel to Schwegman, Lundberg & Woessner. While in private practice, Dr. Seide received many awards and recognitions for her legal expertise.
Before entering legal practice, Dr. Seide was an Assistant Professor of Medical Genetics and Microbiology at Northeastern Ohio Universities College of Medicine, a Genetics Counselor at Children’s Hospital Medical Center of Akron, and a Research Assistant in Immunology at Rockefeller University.
Dr. Seide holds a J.D. from University of Akron School of Law, a Ph.D. in Human Genetics from the City University of New York (Mount Sinai School of Medicine), an M.S. in Immunology from Long Island University, and a B.S. in Microbiology from Syracuse University.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190305005792/en/
CONTACT: For More information about how Shadow Lake Group can help your business please contact:
(416) 569 5105
KEYWORD: NORTH AMERICA CANADA
INDUSTRY KEYWORD: HEALTH OTHER HEALTH PROFESSIONAL SERVICES HUMAN RESOURCES COMMUNICATIONS RESEARCH OTHER COMMUNICATIONS SCIENCE
SOURCE: Shadow Lake Group
Copyright Business Wire 2019.
PUB: 03/05/2019 12:10 PM/DISC: 03/05/2019 12:10 PM